"BINDING SITE FREELIGHT" serum free light chain analysis

Now available PRIVATELY by Gamma Dynacare laboratories.

Provided free by OHIP  at selected Oncology clinics.

Freelite™ Serum Free Light Chain Assays

(UK) Freelite™ is a major breakthrough for the detection and monitoring of Multiple Myeloma (MM) and other B-cell dyscrasia. Freelite™ assays were developed by Binding Site to measure free lambda and free kappa immunoglobulin light chains. Our expertise in the manufacture of antibodies has enabled us to provide a quantifiable, highly specific, automatable free light chain assay for serum.
Significant clinical evidence indicates the benefit of Freelite™ serum free light chain assays in initial screening for monoclonal gammopathies.  Other benefits include the identification of AL amyloidosis and Nonsecretory MM patients missed by conventional electrophoretic methods, use as a prognostic indicator for progression in myeloma, for risk stratification of MGUS patients, and rapid evaluation of treatment efficacy.
Freelite™ is a sensitive, specific marker of kappa and lambda free light chains (FLC) in serum and provides quantitative measurement of:

• Free kappa in serum
• Free lambda in serum
• The serum free kappa/free lambda ratio (κ/λ)

The serum free light chain ratio is a strong indicator of monoclonality and is valuable for distinguishing monoclonal from polyclonal diseases. 

KOREAN-CANADIAN VENTURE for AIDS VACCINE

Sumagen Canada Inc. is a solely owned subsidiary of Sumagen Co., Ltd.
Sumagen Co., Ltd is a Korean pharmaceutical venture company focusing on developing an HIV/AIDS vaccine and is a solely owned subsidiary of Curocom Co., Ltd.  Sumagen is also supporting the ongoing research work at the Schulich School of Medicine and Dentistry, The University of Western Ontario (UWO) for and HCV (Hepatitis C Viru) vaccine.
Dr. Chil Yong Kang, Sumagen's Chief Scientific Officer and also a professor at UWO, developed a vaccine for HIV/AIDS for both therapeutic and prophylactic use with his team.  In 2006, the company opened an office in London at the Stiller Centre, in order to closely support the vaccine development.  The office in London with a staff of six, are managing the project to manufacture the materials for clinical trials, conduct non-clinical studies, and coordinate through a consultant to meet the requirements of the FDA in the United States to obtain approval to conduct human clinical trials.